S. Berthel

发表

Identification of phenyl-pyridine-2-carboxylic acid derivatives as novel cell cycle inhibitors with increased selectivity for cancer cells

I. M. Marks, L. Vassilev, Xuefeng Yin, 2002, Anti-cancer drugs.

Potent, selective MCH-1 receptor antagonists.

S. Berthel, S. Mischke, Y. Qian, 2008, Bioorganic & medicinal chemistry letters.

Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes.

S. Berthel, Y. Qian, D. Choi, 2013, ACS medicinal chemistry letters.

The Tuberculosis Drug Accelerator at year 10: what have we learned?

H. M. Petrassi, Christopher B. Cooper, Robert H Bates, 2021, Nature Medicine.

Novel glucokinase activators: a patent review (2008 – 2010)

S. Berthel, J. Tilley, R. Kester, 2011, Expert opinion on therapeutic patents.

Glucokinase activators for the potential treatment of type 2 diabetes.

Berthel Steven Joseph, S. Berthel, J. Grimsby, 2008, Current topics in medicinal chemistry.

Intuitive Patent Markush Structure Visualization Tool for Medicinal Chemists

Wei Deng, W. Venus So, Steven J. Berthel, 2011, J. Chem. Inf. Model..

[4+2] Cycloaddition Reactions of Indole Derivatives

S. Berthel, R. Kester, F. Firooznia, 2010 .

A Survey of Indolo [2,3-a] carbazole Alkaloids and Related Natural Products

S. Berthel, G. Gribble, 1993 .

Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions

Robert H Bates, M. Vieth, P. Hipskind, 2022, ACS infectious diseases.

Cell-based screening approach for antitumor drug leads which exploits sensitivity differences between normal and cancer cells: identification of two novel cell-cycle inhibitors.

I. M. Marks, L. Vassilev, S. Berthel, 2001, Anti-cancer drug design.

Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules

J. Guenot, S. Berthel, F. Falcioni, 1999, Nature Biotechnology.

7-Phenyl-pyrido[2,3-d]pyrimidine-2,4-diamines: novel and highly selective protein tyrosine phosphatase 1B inhibitors.

S. Berthel, L. Orzechowski, Shiming Li, 2012, Bioorganic & medicinal chemistry letters.

Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.

K. Kaestner, J. Vanderkooi, S. Berthel, 2011, Handbook of experimental pharmacology.

Glucokinase activators as new type 2 diabetes therapeutic agents

S. Berthel, J. Tilley, Ramakanth Sarabu, 2008 .

Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures.

R Crowther, U. Kammlott, J. Guenot, 2000, Journal of medicinal chemistry.

DAIKON: A Data Acquisition, Integration, and Knowledge Capture Web Application for Target-Based Drug Discovery.

J. Sacchettini, S. Berthel, Saswati Panda, 2023, ACS pharmacology & translational science.